  |  |  |  |
Wednesday, 8 September 2010
Novogen agrees to sell its Intellectual Property Portfolio to its subsidiary Marshall Edwards
More news
|
| 
|
|  |
 |
Archived News
Novogen's subsidiary, MEI, begins phenoxodiol Phase II trial at Yale University
Tuesday, 10 December 2002
Novogen Limited’s subsidiary, Marshall Edwards Inc. (LSE-AIM: MSH), has
View full article
Novogen Limited - Annual General Meeting
Friday, 25 October 2002
Novogen wishes to advise the market that the three resolutions put to the
View full article
Novogen Limited Chairman's address at the Annual General Meeting
Friday, 25 October 2002
This year has been exceptionally active and progressive for Novogen. The
View full article
US patent issued to Novogen covering its skin repair compound NV-07α
Thursday, 26 September 2002
The United States patent office has granted a patent to Novogen for its
View full article
Managing Director's letter to shareholders
Thursday, 26 September 2002
Dear Shareholders,
I am pleased to confirm that each of the strategic
View full article
Copy of Marshall Edwards Inc Chairman's report sent to Novogen shareholders
Thursday, 26 September 2002
MARSHALL EDWARDS, INC.
CHAIRMAN’S LETTER TO SHAREHOLDERS
September
View full article
phenoxodiol enters phase II clinical trial in patients with leukemia
Tuesday, 24 September 2002
Novogen Limited’s subsidiary, Marshall Edwards Inc., (LSE-AIM: MSH),
View full article
Major cosmetic opportunity - researchers discover new mode of action for NV-07α
Wednesday, 18 September 2002
Human clinical trialing of pharmaceutical company Novogen Limited’s novel
View full article
Novogen wins Annual Australian Technology Showcase Award
Tuesday, 10 September 2002
Pharmaceutical company, Novogen Limited, has won jointly the third annual
View full article
Novogen's cardio-vascular drug program outstanding in first human clinical trial
Monday, 9 September 2002
Pharmaceutical company Novogen Limited’s NV-04 cardio-vascular drug
View full article
Novogen announces Marshall Edwards Inc. Chairman's letter
Thursday, 5 September 2002
Novogen Limited’s subsidiary, Marshall Edwards Inc., (LSE-AIM: MSH),
View full article
Novogen cash reserves up, loss reduced and R&D programs on schedule
Tuesday, 3 September 2002
Pharmaceutical company Novogen Limited (ASX:NRT, NASDAQ:NVGN), and its
View full article
MEI and Yale University Medical School to develop phenoxodiol for ovarian cancer
Wednesday, 28 August 2002
Novogen Limited’s subsidiary, Marshall Edwards Inc., (LSE-AIM: MSH),
View full article
New evidence confirms red clover isoflavones reduce the frequency and severity of hot flushes
Tuesday, 13 August 2002
There is good news this week for women interested in exploring natural
View full article
MEI and the National Institutes of Health join forces to study the anti-cancer drug, phenoxodiol
Wednesday, 24 July 2002
Novogen’s listed subsidiary, Marshall Edwards Inc. (AIM:MSH), has signed
View full article
EVIDENCE BASED NATURAL ALTERNATIVES FOR MENOPAUSAL AND POST-MENOPAUSAL WOMAN
Friday, 12 July 2002
Information and answers are what women are demanding from their health
View full article
Promensil produces significant cholesterol reduction in women - new study
Monday, 17 June 2002
A research study reported at the 10th World Congress on the Menopause in
View full article
New human clinical trial commences for Novogen's dermatological compound NV-07a
Thursday, 13 June 2002
Novogen has commenced a second human clinical trial of its novel
View full article
Novogen Cardiovascular drug program commences human Phase 1 clinical trial
Wednesday, 29 May 2002
Australian pharmaceutical company, Novogen Limited, has commenced the
View full article
CEO's letter to shareholders
Thursday, 23 May 2002
23 May, 2002
Dear Shareholders,
There have been many exciting
View full article
Marshall Edwards raises $US 10M and lists on the UK AIM
Wednesday, 22 May 2002
Marshall Edwards Inc., (MEI), the US subsidiary of Novogen Limited, has
View full article
Novogen intends to apply for a MEI listing on the A I M of the London Stock Exchange plc
Thursday, 9 May 2002
Marshall Edwards, Inc. (MEI), the US oncology subsidiary of Novogen
View full article
Phenoxodiol stabilises cancer progression with minimal toxicity
Tuesday, 9 April 2002
(San Francisco, California, USA) – Preliminary US clinical trial results
View full article
Novogen receives US patent covering red clover isoflavone and osteoporosis
Wednesday, 27 February 2002
Pharmaceutical company Novogen Limited has been granted a patent in the
View full article
Half yearly review
Wednesday, 27 February 2002
The Directors’ commentary to the half year ending 31 December, 2001
View full article
Novogen retains cash and reduces loss to drive drug development
Wednesday, 27 February 2002
Prudent management of OTC promotional spending and other costs has
View full article
Novogen red clover dietary supplement inhibits growth of prostate cancer cells in human trial
Monday, 11 February 2002
New human clinical trial data has revealed that Novogen Limited’s red
View full article
Promensil: only isoflavone supplement delivering on its promise to menopausal women
Monday, 4 February 2002
A recent study of isoflavone supplements highlights the inconsistencies
View full article
Novogen receives first royalty payment from DuPont Company.
Monday, 7 January 2002
Pharmaceutical company, Novogen Limited, today announced receipt of the
View full article
Novogen anti-cancer drug, phenoxodiol, to start trial in patients with leukemia
Wednesday, 19 December 2001
(SYDNEY, AUSTRALIA) Australian pharmaceutical company, Novogen Limited,
View full article
Novogen responds to ASX price query
Monday, 3 December 2001
Ms Caitlin Chau
Australian Stock Exchange
Companies Advisor
Level 6,
View full article
Phenoxodiol Explanatory Notes
Thursday, 22 November 2001
PHENOXODIOL
Anti-cancer drug development has had a lot of theories
View full article
US clinical trial on Novogen’s experimental anti-cancer drug, phenoxodiol, to be expedited.
Monday, 19 November 2001
ASX & MEDIA RELEASE 19 NOVEMBER, 2001
US CLINICAL TRIAL
View full article
Clinical trial shows Promensil offers relief of common breast condition
Tuesday, 13 November 2001
The European medical journal The Breast, today reported that the product,
View full article
Novogen’s Phenoxodiol proves well tolerated with demonstrated activity in cancer patients
Wednesday, 31 October 2001
Data has been presented at a US medical conference from the first human
View full article
NOVOGEN LIMITED – ANNUAL GENERAL MEETING
Friday, 26 October 2001
Novogen wishes to advise the market that the three resolutions put to the
View full article
CEO's Comments - October 2001
Friday, 12 October 2001
Novogen is now undertaking a concerted program of clinical trials. This
View full article
PROMENSIL - RESULTS FROM A NEW CLINICAL STUDY
Monday, 8 October 2001
ASX & MEDIA ANNOUNCEMENT 8 OCTOBER 2001
NEW CLINICAL STUDY CONFIRMS
View full article
HUMAN CLINICAL TRIALS COMMENCE - NV-07
Thursday, 27 September 2001
HUMAN CLINICAL TRIALS TO COMMENCE OF NOVOGEN’S SKIN REPAIR COMPOUND
View full article
NOVOGEN APPOINTS NEW DIRECTOR
Monday, 3 September 2001
ASX & MEDIA RELEASE 3 SEPTEMBER 2001
NOVOGEN APPOINTS NEW
View full article
NOVOGEN RESULTS
Thursday, 30 August 2001
ASX & MEDIA RELEASE 30 AUGUST 2001
NOVOGEN SALES AND CASH UP, AND
View full article
CANCER DRUG ORAL VERSION COMMENCES TRIAL
Wednesday, 15 August 2001
NOVOGEN COMMENCES CLINICAL TRIAL OF ORAL VERSION OF CANCER DRUG
View full article
US JOURNAL PUBLISHES BONE & HEART FINDINGS
Monday, 30 July 2001
ASX & MEDIA RELEASE 30 JULY 2001
US JOURNAL PUBLISHES CLINICAL STUDY
View full article
Novogen Research & Development Review
Thursday, 26 July 2001
CLICK HERE TO DOWNLOAD
View full article
Cancer announcement at US Conference
Wednesday, 13 June 2001
AUSTRALIAN SCIENTISTS ANNOUNCE IMPORTANT CANCER DISCOVERY AT US
View full article
$21m RAISED FOR PHENOXODIOL CLINICAL STUDIES
Thursday, 31 May 2001
NOVOGEN RAISES $21 MILLION TO FUND PHENOXODIOL CLINICAL
View full article
US CLINICAL STUDY OF PHENOXODIOL COMMENCES
Monday, 28 May 2001
US CLINICAL STUDY OF NOVOGEN ANTI-CANCER DRUG PHENOXODIOL
View full article
Clarification of Media Reports......
Thursday, 24 May 2001
CLARIFICATION OF MEDIA REPORTS RE PHENOXODIOL CLINICAL STUDIES
Novogen
View full article
Bone Health Claim For Novogen’s Promensil™
Monday, 9 April 2001
Pharmaceutical company Novogen’s natural isoflavone product
View full article
Novogen Lifts First Half OTC Sales ……
Friday, 16 February 2001
Novogen Lifts First Half OTC Sales & Coverage To Drive R&D
View full article
Novogen Receives FDA Approval For US Human Testing
Monday, 29 January 2001
Novogen today announced that it had received notification from the U.S.
View full article
Prime Minister Comments on R&D Grant to Novogen
Tuesday, 23 January 2001
JOHN HOWARD MP
MEMBER FOR BENNELONG
PRIME MINISTER
MEDIA
View full article
Novogen Receives $3.7m Grant for NV-07...........
Tuesday, 16 January 2001
Novogen Receives $3.7m Start Grant For Development of its
View full article
Second Phenoxodiol Study Begins
Monday, 8 January 2001
NOVOGEN’S NOVEL ANTI-CANCER DRUG RECEIVES APPROVAL TO COMMENCE
View full article
Confirmation of Novogen Board Changes
Monday, 1 January 2001
Novogen today confirmed the announcement made at the Annual General
View full article
Novogen Shares Collaborative R&D Award.......
Tuesday, 21 November 2000
Novogen Shares Collaborative R&D Award With University of
View full article
New Promensil Study - Cholesterol Benefit
Tuesday, 31 October 2000
NEW PROMENSIL STUDY CONFIRMS BLOOD CHOLESTEROL HEALTH
View full article
NOVOGEN SALES INCREASE ................
Thursday, 31 August 2000
NOVOGEN SALES INCREASE AND DRUG DEVELOPMENT PROGRAMS
View full article
NOVOGEN ANTI-CANCER DRUG TRIALS ADVANCE
Monday, 21 August 2000
Australian pharmaceutical company, Novogen, today announced that its
View full article
Promensil offers additional health benefits
Thursday, 6 July 2000
Results from a new clinical study of Promensil provide important evidence
View full article
Novogen Share Issue
Thursday, 22 June 2000
The Directors of Novogen Limited have announced the issue of 5.018
View full article
Novogen launches Rimostil
Thursday, 22 June 2000
Science has demonstrated that natural plant isoflavones produce an
View full article
Trinovin™ alleviates prostate enlargement symptoms
Wednesday, 21 June 2000
Study shows red clover supplementation improves quality of
View full article
Anti-Cancer Drug Passes First Clinical Hurdle
Tuesday, 6 June 2000
Australian pharmaceutical company, Novogen Limited, today announced the
View full article
Trinovin Clinical Trial Results
Monday, 5 June 2000
New Isoflavone Dietary Supplement Trinovin Offers a Novel OTC Solution to
View full article
Novogen NASDAQ Listing Upgraded to National Board
Wednesday, 24 May 2000
ASX listed pharmaceutical company, Novogen Limited (code: NRT) has
View full article
New Research Results For NV-04
Thursday, 4 May 2000
New research strengthens expectation for Novogen cardiovascular
View full article
Novogen Withdraws Advertisement
Wednesday, 22 March 2000
ASX listed biopharmaceutical company, Novogen Limited, has received a
View full article
Novogen Clinical Data Supports Promensil Efficacy
Tuesday, 21 March 2000
ASX listed biopharmaceutical company, Novogen Limited, today said that
View full article
Novogen Advertising
Tuesday, 21 March 2000
ASX listed biopharmaceutical company Novogen Limited said all its
View full article
Novogen Lifts First Half Sales.....
Monday, 14 February 2000
Novogen Lifts First Half Sales and Consolidates Global
View full article
Novogen Anti-Cancer Drug Enters Phase I Trials
Monday, 7 February 2000
Australian pharmaceutical company, Novogen Limited, today announced that
View full article
New Milestone For Novogen Cardiovascular Drug
Monday, 31 January 2000
Australian pharmaceutical company, Novogen Limited today announced that
View full article
Novogen Launches Promensil In Canada
Monday, 24 January 2000
Australian pharmaceutical company Novogen Limited, has launched
View full article
Novogen’s First Chairman Retires
Friday, 24 December 1999
Novogen Limited today announced the retirement of Professor Marsh
View full article
New Promensil Study Reveals Breast Disease Benefit
Tuesday, 21 December 1999
Australian pharmaceutical company, Novogen Limited, announced today that
View full article
|
|
|
